**Supplemental Digital Content 3.** Administration characteristics and outcomes in patients approved for COVID-19 therapy

|  |  |  |  |
| --- | --- | --- | --- |
| **Therapy** | **Sotrovimab**  **(N=16)** | **Nirmatrelvir/Ritonavir**  **(N=12)** | **Remdesivir**  **(N=38)** |
| **Median age in years (range)** | 16 (12-19) | 14.5 (12-24) | 8 (0.6-21) |
| **Median days from start of infection to first dose (range)** | 3 (0-6) | 3 (1-6) | 2 (0-9) |
| **Therapy approved but not given, N (%)**  Family declined  Symptoms improved  Not arranged in time  No infusion center capacity  Provider unable to prescribe  Baseline ALT too high  Unknown | 5 (31)  1  2  1  0  n/a  n/a  1 | 3 (25)  1  0  0  n/a  1  n/a  1 | 11 (29)  5  2  0  1  n/a  2  1 |
| **Location of administration, N (%)**  Inpatient  Infusion center  Emergency department  Mixed | N=11  2 (18)a  6 (55)  3 (27)  0 | N=9  n/a  n/a  n/a  n/a | N=27  16 (59)  7 (26)  1 (4)  1 (4) |
| **Adverse events during administration** | 1b | 0 | 0 |
| **Emergency department visitsc** | 1b | 1d |  |
| **Hospitalizationsc** | 1e |  | 1f |

a. Hospitalized after positive SARS-CoV-2 test for non-COVID-19 related reasons

b. Chest pain during infusion and for 2 days afterwards, leading to ED visit

c. Within 7 days of treatment request, excludes therapy-specific visits or admissions

d. Shortness of breath, discharged from ED in good condition

e. Therapy approved but not administered; admitted for prolonged fever.

f. Admission for fever and neutropenia following completion of 3-day remdesivir treatment